CUSIP: 81362J100
Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
7,335,287
-
Share change
-
-529,226
-
Total reported value
-
$5,871,989
-
Price per share
-
$0.80
-
Number of holders
-
38
-
Value change
-
-$422,768
-
Number of buys
-
9
-
Number of sells
-
12
Quarterly Holders Quick Answers
What is CUSIP 81362J100?
CUSIP 81362J100 identifies EYES - SECOND SIGHT MED PRODS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2019
-
Previous quarter:
Q1 2019
Recent filing periods for CUSIP 81362J100:
Institutional Holders of SECOND SIGHT MED PRODS INC - COM (EYES) as of Q2 2019
As of 30 Jun 2019,
SECOND SIGHT MED PRODS INC - COM (EYES) was held by
38 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,335,287 shares.
The largest 10 holders included
Versant Venture Management, LLC, VANGUARD GROUP INC, Sigma Planning Corp, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, HBK Sorce Advisory LLC, Glassman Wealth Services, Fore Capital, LLC, WILEY BROS.-AINTREE CAPITAL, LLC, and NORTHERN TRUST CORP.
This page lists
38
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.